drugset / Trial / NCT01964027
The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study is to determine the response rate and safety profile of irinotecan plus epirubicin as the second-line chemotherapy for advanced gastric cancer and fully evaluate the feasibility and effectiveness of the regime.
Timeline
- Start
- 2013-10
- Primary completion
- 2014-07
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epirubicin | Small molecule | 50 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |